5 employees
Lusaris Therapeutics develops small-molecule neuroplastogen therapeutics for neuropsychiatric and neurological disorders.
2021
$60M
from 1 investors over 1 rounds
Lusaris Therapeutics raised $60M on November 2, 2022
Investors: RA Capital Management, L.P.